article · Current Issues in Molecular Biology
Diarrheagenic Escherichia coli (DEC) is a leading enteric pathogen in children under five in sub-Saharan Africa, yet conventional targeted assays fail to capture mixed virulence signatures or provide quantitative context relative to E. coli carriage. We applied a virulence-aware nanopore metagenomics workflow to characterise DEC pathotype distribution, mixed signatures, and virulence gene burden in 126 under-five stool metagenomes from six Tanzanian regions. Virulence support was quantified as aligned bases normalised to per-sample E. coli-aligned bases, termed GPMB (gene bases per million E. coli-aligned bases). At least one DEC virulence family was detected in 79/126 (62.7%) samples. afa/dra (diffusely adherent E. coli [DAEC] marker) was the most prevalent family (46/126, 36.5%); DAEC-containing pathotypes accounted for 46/79 (58.2%) of all assigned calls across all six regions. Mixed signatures occurred in 21/79 (26.6%) assigned samples, most commonly DAEC + enteroaggregative E. coli (EAEC) (n = 11). Enterotoxigenic E. coli (ETEC) was geographically concentrated in Mwanza. Age-stratified analysis revealed declining DAEC prevalence with age. Multivariable logistic regression found no significant independent associations between DEC positivity and age, sex, or rainfall. Unassigned samples had 6.8-fold lower E. coli carriage depth, implicating sequencing depth rather than pathotype absence as the primary non-detection driver. DAEC and EAEC should be elevated as priority DEC surveillance targets in Tanzania.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/cimb48080794
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.